- Conditions
- Healthy Subjects
- Interventions
- Glepaglutide
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Short Bowel Syndrome (SBS)
- Interventions
- Glepaglutide 10 mg
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more
- Conditions
- Short Bowel Syndrome
- Interventions
- Glepaglutide, Placebo
- Drug · Other
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 2 more
- Conditions
- Short Bowel Syndrome
- Interventions
- Glepaglutide
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Rochester, Minnesota • Omaha, Nebraska + 1 more
- Conditions
- Short Bowel Syndrome
- Interventions
- glepaglutide
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more